ReviewJournal of translational internal medicine
Viral hepatitis in hemodialysis: An update.
Review in Journal of translational internal medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 84 citations in OpenAlex.
- Healthcare-associated hepatitis B and C transmission to patients in the EU/EEA and UK: a systematic review of reported outbreaks between 2006 and 2021.BMC public health · 2022Pooled it
- Clinical practice guideline management of blood borne viruses within the haemodialysis unit.BMC nephrology · 2019Guideline
- Erythropoietin in Acute Kidney Injury (EAKI): a pragmatic randomized clinical trial.BMC nephrology · 2022Trial
- Telbivudine for renal transplant recipients with chronic hepatitis B infection: a randomized controlled trial with early termination.Clinical and experimental nephrology · 2020Trial
- Hepatitis B in Hemodialysis: Serologic Dynamics and Implications for Care.Journal of clinical medicine · 2026Article
- The relationship between self-efficacy/resilience and the mental health status of hemodialysis nurses: multiple mediation effects of insomnia and fatigue.Frontiers in psychology · 2025Article
- Prevalence of occult hepatitis C virus infection (OCI) among hemodialysis patients; a cross-sectional study from Lorestan Province, Western Iran.Virusdisease · 2024Article
- Hepatitis E Virus Genotype 3 among Hemodialysis Patients in Mexico: First Identification of Chronic Infection.Pathogens (Basel, Switzerland) · 2024Article
- Impaired humoral immune response to hepatitis B vaccine in patients on maintenance hemodialysis.Saudi journal of biological sciences · 2023Article
- Advanced Theranostic Strategies for Viral Hepatitis Using Carbon Nanostructures.Micromachines · 2023Review
- Contribution of Hepatitis B Contribution to Anemia in Dialysis Patients with Chronic Renal Failure, Iraq.Archives of Razi Institute · 2022Article
- Robust hepatitis B vaccine-reactive T cell responses in failed humoral immunity.Molecular therapy. Methods & clinical development · 2021Article
- Dried blood spot sampling as an alternative for the improvement of hepatitis B and C diagnosis in key populations.World journal of hepatology · 2021Article
- Risk factors of hepatocellular carcinoma in type 2 diabetes patients: A two-centre study in a developing country.PloS one · 2021Article
- Blood-borne viral infections in pediatric hemodialysis.Pediatric nephrology (Berlin, Germany) · 2019Article
- Response to single dose hepatitis B vaccine in Congolese non-HIV hemodialysis patients: a prospective observational study.The Pan African medical journal · 2019Observational
- Oncogenic Viral Infections Among Iranian Hemodialysis Patients: A Systematic Review.International journal of preventive medicine · 2019Article
- Decline in hepatitis B and C prevalence among hemodialysis patients in Tocantins, Northern Brazil.Revista do Instituto de Medicina Tropical de Sao Paulo · 2018Article
- Seroprevalence of human immunodeficiency virus, hepatitis B and C viruses among haemodialysis patients in two newly opened centres in Cameroon.The Pan African medical journal · 2017Article
- INASL-ISN Joint Position Statements on Management of Patients with Simultaneous Liver and Kidney Disease.Journal of clinical and experimental hepatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis outbreaks in hemodialysis (HD) patients and staff were reported in the late 1960s, and a number of hepatotropic viruses transmitted by blood and other body fluids have been identified. Hepatitis B virus (HBV) was the first significant hepatotropic virus to be identified in HD centers. HBV infection has been effectively controlled by active vaccination, screening of blood donors, the use of erythropoietin and segregation of HBV carriers. Hepatitis delta virus is a defective virus that can only infect HBV-positive individuals. Hepatitis C virus (HCV) is the most significant cause of non-A, non-B hepatitis and is mainly transmitted by blood transfusion. The introduction in 1990 of routine screening of blood donors for HCV contributed significantly to the control of HCV transmission. An effective HCV vaccine remains an unsolved challenge; however, pegylation of interferon-alfa has made it possible to treat HCV-positive dialysis patients. Unexplained sporadic outbreaks of hepatitis by the mid-1990s prompted the discovery of hepatitis G virus, hepatitis GB virus C and the TT virus. The vigilant observation of guidelines on universal precaution and regular virologic testing are the cornerstones of the effective control of chronic hepatitis in the setting of HD. Major recent advances in the viral diagnosis technology and the development of new oral, direct-acting antiviral agents allow early diagnosis and better therapeutic response. The current update will review the recent developments, controversies and new treatment of viral hepatitis in HD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.